Literature DB >> 25717045

Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines.

Davide Capodanno1, Dominick J Angiolillo2.   

Abstract

Entities:  

Keywords:  acute coronary syndrome; antiplatelet therapy; percutaneous coronary intervention

Mesh：

Substances：

Year:  2015        PMID： 25717045     DOI： 10.1161/CIRCINTERVENTIONS.114.002301

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN： 1941-7640            Impact factor:   6.546


× No keyword cloud information.
  12 in total

Review 1.  Switching P2Y12-receptor inhibitors in patients with coronary artery disease.

Authors:  Fabiana Rollini; Francesco Franchi; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2015-08-18       Impact factor: 32.419

Review 2.  Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.

Authors:  Ana Lucrecia Marcano; José Luis Ferreiro
Journal:  Curr Atheroscler Rep       Date:  2016-11       Impact factor: 5.113

Review 3.  Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management.

Authors:  Davide Cao; Rishi Chandiramani; Davide Capodanno; Jeffrey S Berger; Matthew A Levin; Mary T Hawn; Dominick J Angiolillo; Roxana Mehran
Journal:  Nat Rev Cardiol       Date:  2020-08-05       Impact factor: 32.419

Review 4.  Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes.

Authors:  Daniel R Mangels; Ashwin Nathan; Sony Tuteja; Jay Giri; Taisei Kobayashi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-02-27

Review 5.  Role of genetic testing in patients undergoing percutaneous coronary intervention.

Authors:  Jae Youn Moon; Francesco Franchi; Fabiana Rollini; Jose R Rivas Rios; Megha Kureti; Larisa H Cavallari; Dominick J Angiolillo
Journal:  Expert Rev Clin Pharmacol       Date:  2017-10-12       Impact factor: 5.045

Review 6.  Antithrombotic therapy for patients with STEMI undergoing primary PCI.

Authors:  Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2017-02-23       Impact factor: 32.419

7.  P2Y12 inhibitor pretreatment in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis.

Authors:  Longhui Yan; Yan Zhou; Zhangjie Yu; Mengmei Xuan; Buyun Xu; Fang Peng
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

Review 8.  Bleeding avoidance strategies in percutaneous coronary intervention.

Authors:  Davide Capodanno; Deepak L Bhatt; C Michael Gibson; Stefan James; Takeshi Kimura; Roxana Mehran; Sunil V Rao; Philippe Gabriel Steg; Philip Urban; Marco Valgimigli; Stephan Windecker; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2021-08-23       Impact factor: 32.419

9.  Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.

Authors:  Joseph M Sweeny; Dominick J Angiolillo; Francesco Franchi; Fabiana Rollini; Ron Waksman; Ganesh Raveendran; George Dangas; Naeem D Khan; Glenn F Carlson; Yonggang Zhao; Renli Teng; Roxana Mehran
Journal:  J Am Heart Assoc       Date:  2017-03-29       Impact factor: 5.501

10.  Contemporary use of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction referred to primary percutaneous coronary interventions in Poland: Data from ORPKI national registry.

Authors:  Tomasz Rakowski; Zbigniew Siudak; Artur Dziewierz; Krzysztof Plens; Paweł Kleczyński; Dariusz Dudek
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.